Skip to main content

Advertisement

SpringerLink
Log in

Psoriasis triggered by infliximab in a patient with Behçet’s disease

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To report a case of psoriasis triggered by anti-tumor necrosis factor-alpha (TNF-α) therapy in a uveitis patient with Behçet’s disease.

Case report

A 34-year-old man with established Behçet’s disease was started on infliximab therapy for recurrent uveitis and showed an excellent response. After 2 years of infliximab treatment, he developed erythematous scaly plaques on both of his palms and heels. No clinical or serological evidence of infection was found, and there was no personal/family history of psoriasis. Histological examination of one lesion showed that it was consistent with psoriasis. Because of the development of hyperkeratotic skin lesions consistent with guttate psoriasis, the infliximab treatment was discontinued. Six months later, the psoriasis had resolved.

Conclusions

Blockade of TNF-α is an effective treatment for psoriasis as well as Behçet’s disease. However, we have to consider new-onset psoriasis as an adverse side effect that can be triggered by anti-TNF-α therapy in Behçet’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol. 2002;29:667–77.

    PubMed  CAS  Google Scholar 

  2. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–9.

    Article  PubMed  CAS  Google Scholar 

  3. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol. 2002;46:886–91.

    Article  PubMed  Google Scholar 

  4. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–8.

    PubMed  CAS  Google Scholar 

  5. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404–6.

    PubMed  CAS  Google Scholar 

  6. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus cyclosporine during the initial 6-month treatment period in Behçet disease. Br J Opthalmol. 2010;94:284–8.

    Article  Google Scholar 

  7. Keino H, Okada AA, Watanabe T, Taki W. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–50.

    Article  PubMed  Google Scholar 

  8. Wang Y, Gaudio PA. Infliximab therapy for 2 patients with Vogt–Koyanagi–Harada syndrome. Ocul Immunol Inflamm. 2008;16:167–71.

    Article  PubMed  CAS  Google Scholar 

  9. Ito T, Sonoda KH, Hijioka K, Fujimoto T, Ishibashi T. Acquired resistance to infliximab against uveitis due to Behçet’s disease after one year of administration. Jpn J Ophthalmol. 2010;54:502–4.

    Article  PubMed  Google Scholar 

  10. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy. Arthr Rheum. 2005;52:2513–8.

    Article  CAS  Google Scholar 

  11. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sörensen H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis. 2006;65:405–7.

    Article  PubMed  CAS  Google Scholar 

  12. Matthews C, Rogers S, FitzGerald O. Development of new-onset psoriasis while on anti-TNFalpha treatment. Ann Rheum Dis. 2006;65:1529–30.

    Article  PubMed  CAS  Google Scholar 

  13. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthr Rheum. 2010;40:233–40.

    Article  CAS  Google Scholar 

  14. Laga AC, Vleugels RA, Qureshi AA, Velazquez EF. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies. Am J Dermatopathol. 2010;32:568–73.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Ophthalmology and Visual Science, Tokyo Medical and Dental University Graduate School of Medicine and Dental Sciences, Tokyo, Japan

    Yuko Kawazoe, Sunao Sugita, Yukiko Yamada & Manabu Mochizuki

  2. Laboratory for Retinal Regeneration, RIKEN Center for Developmental Biology, 2-2-3 Minatojima-minamimachi, Chuo-ku, Kobe, 650-0047, Japan

    Sunao Sugita

  3. Department of Dermatology, Faculty of Medicine, Tokyo Medical and Dental University Graduate School of Medicine and Dental Sciences, Tokyo, Japan

    Ai Akino

  4. Division of Surgical Pathology, Faculty of Medicine, Tokyo Medical and Dental University Graduate School of Medicine and Dental Sciences, Tokyo, Japan

    Keiko Miura

Authors
  1. Yuko Kawazoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sunao Sugita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukiko Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ai Akino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keiko Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manabu Mochizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sunao Sugita.

About this article

Cite this article

Kawazoe, Y., Sugita, S., Yamada, Y. et al. Psoriasis triggered by infliximab in a patient with Behçet’s disease. Jpn J Ophthalmol 57, 95–97 (2013). https://doi.org/10.1007/s10384-012-0198-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-012-0198-4

Keywords

Search

Navigation